Results of the preclinical multicenter randomized controlled paclitaxel-induced neuropathy prevention replication study (PINPRICS)
Abstract Objective Chemotherapy-induced peripheral neuropathy (CIPN) is a frequent and serious side effect of many cytotoxic drugs, including paclitaxel. Despite the identification of treatment options in animal models, clinical trials for the treatment or prevention of CIPN have been negative. Majo...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-04-01
|
| Series: | BMC Research Notes |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13104-025-07206-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850201680453304320 |
|---|---|
| author | Wolfgang Boehmerle Tim Hagenacker Markus Leo Linda-Isabell Schmitt Helmar C. Lehmann Ines Klein Regina Stegherr Frank Konietschke Matthias Endres Petra Huehnchen |
| author_facet | Wolfgang Boehmerle Tim Hagenacker Markus Leo Linda-Isabell Schmitt Helmar C. Lehmann Ines Klein Regina Stegherr Frank Konietschke Matthias Endres Petra Huehnchen |
| author_sort | Wolfgang Boehmerle |
| collection | DOAJ |
| description | Abstract Objective Chemotherapy-induced peripheral neuropathy (CIPN) is a frequent and serious side effect of many cytotoxic drugs, including paclitaxel. Despite the identification of treatment options in animal models, clinical trials for the treatment or prevention of CIPN have been negative. Major challenges for successful clinical translation of preclinical data include a lack of reproducibility and randomization, small sample sizes and insufficient statistical tests. We therefore conducted a confirmatory, preclinical multicenter randomized controlled replication trial to test the safety and efficacy of three drugs for preventing paclitaxel-induced polyneuropathy: (1) nilotinib, (2) lithium carbonate and (3) interleukin-6-neutralizing antibodies. We preregistered the data analysis plan as well as the two-step study protocol: the optimal doses of the three compounds were assessed first and then tested in a mouse breast cancer xenograft model to compare safety and efficacy. Results Unfortunately, toxicity of intraperitoneally administered nilotinib in combination with paclitaxel was observed, and higher-than-expected tumor growth resulted in a lack of power when the trial was analyzed. Thus, although lithium carbonate and IL-6-neutralizing antibodies tended toward neuroprotection, the differences between these groups were not statistically significant. However, the PINPRICS study ultimately still provides important lessons with regard to the planning and conduction of multicenter preclinical trials. |
| format | Article |
| id | doaj-art-d941fe9b369749dbae1f88178dab6dc6 |
| institution | OA Journals |
| issn | 1756-0500 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Research Notes |
| spelling | doaj-art-d941fe9b369749dbae1f88178dab6dc62025-08-20T02:11:57ZengBMCBMC Research Notes1756-05002025-04-011811910.1186/s13104-025-07206-2Results of the preclinical multicenter randomized controlled paclitaxel-induced neuropathy prevention replication study (PINPRICS)Wolfgang Boehmerle0Tim Hagenacker1Markus Leo2Linda-Isabell Schmitt3Helmar C. Lehmann4Ines Klein5Regina Stegherr6Frank Konietschke7Matthias Endres8Petra Huehnchen9Klinik und Hochschulambulanz für Neurologie, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu BerlinDepartment of Neurology and Center for Translational Neuro- and Behavioral Science, University Hospital EssenDepartment of Neurology and Center for Translational Neuro- and Behavioral Science, University Hospital EssenDepartment of Neurology and Center for Translational Neuro- and Behavioral Science, University Hospital EssenDepartment of Neurology, Medical Faculty, University Hospital CologneDepartment of Neurology, Medical Faculty, University Hospital CologneInstitut für Biometrie und Klinische Epidemiologie, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu BerlinInstitut für Biometrie und Klinische Epidemiologie, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu BerlinKlinik und Hochschulambulanz für Neurologie, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu BerlinKlinik und Hochschulambulanz für Neurologie, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu BerlinAbstract Objective Chemotherapy-induced peripheral neuropathy (CIPN) is a frequent and serious side effect of many cytotoxic drugs, including paclitaxel. Despite the identification of treatment options in animal models, clinical trials for the treatment or prevention of CIPN have been negative. Major challenges for successful clinical translation of preclinical data include a lack of reproducibility and randomization, small sample sizes and insufficient statistical tests. We therefore conducted a confirmatory, preclinical multicenter randomized controlled replication trial to test the safety and efficacy of three drugs for preventing paclitaxel-induced polyneuropathy: (1) nilotinib, (2) lithium carbonate and (3) interleukin-6-neutralizing antibodies. We preregistered the data analysis plan as well as the two-step study protocol: the optimal doses of the three compounds were assessed first and then tested in a mouse breast cancer xenograft model to compare safety and efficacy. Results Unfortunately, toxicity of intraperitoneally administered nilotinib in combination with paclitaxel was observed, and higher-than-expected tumor growth resulted in a lack of power when the trial was analyzed. Thus, although lithium carbonate and IL-6-neutralizing antibodies tended toward neuroprotection, the differences between these groups were not statistically significant. However, the PINPRICS study ultimately still provides important lessons with regard to the planning and conduction of multicenter preclinical trials.https://doi.org/10.1186/s13104-025-07206-2Chemotherapy-induced polyneuropathyNeuropathic painNeuroprotectionPreclinical replication study |
| spellingShingle | Wolfgang Boehmerle Tim Hagenacker Markus Leo Linda-Isabell Schmitt Helmar C. Lehmann Ines Klein Regina Stegherr Frank Konietschke Matthias Endres Petra Huehnchen Results of the preclinical multicenter randomized controlled paclitaxel-induced neuropathy prevention replication study (PINPRICS) BMC Research Notes Chemotherapy-induced polyneuropathy Neuropathic pain Neuroprotection Preclinical replication study |
| title | Results of the preclinical multicenter randomized controlled paclitaxel-induced neuropathy prevention replication study (PINPRICS) |
| title_full | Results of the preclinical multicenter randomized controlled paclitaxel-induced neuropathy prevention replication study (PINPRICS) |
| title_fullStr | Results of the preclinical multicenter randomized controlled paclitaxel-induced neuropathy prevention replication study (PINPRICS) |
| title_full_unstemmed | Results of the preclinical multicenter randomized controlled paclitaxel-induced neuropathy prevention replication study (PINPRICS) |
| title_short | Results of the preclinical multicenter randomized controlled paclitaxel-induced neuropathy prevention replication study (PINPRICS) |
| title_sort | results of the preclinical multicenter randomized controlled paclitaxel induced neuropathy prevention replication study pinprics |
| topic | Chemotherapy-induced polyneuropathy Neuropathic pain Neuroprotection Preclinical replication study |
| url | https://doi.org/10.1186/s13104-025-07206-2 |
| work_keys_str_mv | AT wolfgangboehmerle resultsofthepreclinicalmulticenterrandomizedcontrolledpaclitaxelinducedneuropathypreventionreplicationstudypinprics AT timhagenacker resultsofthepreclinicalmulticenterrandomizedcontrolledpaclitaxelinducedneuropathypreventionreplicationstudypinprics AT markusleo resultsofthepreclinicalmulticenterrandomizedcontrolledpaclitaxelinducedneuropathypreventionreplicationstudypinprics AT lindaisabellschmitt resultsofthepreclinicalmulticenterrandomizedcontrolledpaclitaxelinducedneuropathypreventionreplicationstudypinprics AT helmarclehmann resultsofthepreclinicalmulticenterrandomizedcontrolledpaclitaxelinducedneuropathypreventionreplicationstudypinprics AT inesklein resultsofthepreclinicalmulticenterrandomizedcontrolledpaclitaxelinducedneuropathypreventionreplicationstudypinprics AT reginastegherr resultsofthepreclinicalmulticenterrandomizedcontrolledpaclitaxelinducedneuropathypreventionreplicationstudypinprics AT frankkonietschke resultsofthepreclinicalmulticenterrandomizedcontrolledpaclitaxelinducedneuropathypreventionreplicationstudypinprics AT matthiasendres resultsofthepreclinicalmulticenterrandomizedcontrolledpaclitaxelinducedneuropathypreventionreplicationstudypinprics AT petrahuehnchen resultsofthepreclinicalmulticenterrandomizedcontrolledpaclitaxelinducedneuropathypreventionreplicationstudypinprics |